Navigation Links
Light Sciences Oncology Raises $40.1 Million in Series C Financing
Date:7/15/2008

Proceeds to Fund Completion of Phase III Trials of Light Infusion Therapy in Hepatocellular Carcinoma and Metastatic Colorectal Cancer and Phase I/II

and Phase IIa Benign Prostatic Hyperplasia Studies

BELLEVUE, Wash., July 15 /PRNewswire/ -- Light Sciences Oncology, Inc. (LSO), a privately held company developing Light Infusion Therapy(TM) (Litx(TM)) to treat cancer and other conditions, today announced that it has raised $40.1 million in a Series C round of financing. The company raised $97 million in its first two rounds of financing. Investor names were not disclosed.

LSO plans to use the funds in the continued development of Light Infusion Therapy (Litx), which includes two ongoing Phase III clinical trials in patients with hepatocellular carcinoma and metastatic colorectal cancer, a planned Phase III trial in glioblastoma multiforme (brain cancer), and early stage clinical trials in benign prostatic hyperplasia (BPH).

"We are approaching exciting milestones in the development of Litx, including the completion of enrollment in our Phase III primary liver cancer trial," said Llew Keltner, M.D., Ph.D., president and chief executive officer of Light Sciences Oncology. "The Series C funds combined with our substantial cash reserves will allow us to continue to move forward with all aspects of our development plan in a timely manner."

Leerink Swann LLC acted as exclusive placement agent and exclusive financial advisor in connection with the transaction.

About Light Sciences Oncology

Light Sciences Oncology, Inc. (LSO) is developing Light Infusion Therapy(TM) (Litx(TM)) to provide safer and more effective treatment for cancer and other conditions. In addition to the Phase III trials in hepatocellular carcinoma and colorectal cancer metastatic to the liver, the company has completed a Phase II clinical trial of Litx in glioma and plans to initiate a Phase III trial in glioma during the second half of 2008. LSO has widened the scope of potential therapeutic applications of the versatile Litx platform to include benign neoplasms such as benign prostatic hyperplasia (BPH), neurofibromas, and uterine fibroids, as well as vascular disease and dermatology. The company has positioned itself for growth with a strong portfolio of intellectual property, innovative applications in development, and an exceptionally talented team.

Contact:

Robert M. Littauer

Vice President, Chief Financial Officer and Treasurer

1-425-957-8900

bobl@lsoncology.com

Llew Keltner, M.D., Ph.D.

President and CEO

1-425-957-8900

dr_llew@lsoncology.com

http://www.lsoncology.com


'/>"/>
SOURCE Light Sciences Oncology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
3. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
4. Public Forum to Discuss Addiction as a Treatable Disease and Highlight National Alcohol and Drug Addiction Recovery Month
5. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
6. SuperGens Novel Hypomethylating Agent Highlighted at AACR Plenary Session
7. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
8. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
9. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
10. Mitchell, Military TBI Task Force Highlight the Importance of Traumatic Brain Injury Research; Mitchell Endorses Ground Breaking Traumatic Brain Injury Study
11. Research Highlights Potential Benefits of Telemedicine in Treating Eye Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
(Date:6/23/2016)... June 23, 2016 Bracket , a leading ... next generation clinical outcomes platform, Bracket eCOA (SM) 6.0, ... June 26 – 30, 2016 in Philadelphia ... Clinical Outcome Assessment product of its kind to fully integrate ... Bracket eCOA 6.0 is a flexible platform for electronic ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
Breaking Medicine News(10 mins):